Education
About Us
Working with TipRanks
Follow Us
Prokidney Corp. (PROK)
:PROK
PROK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.46 - $7.13
Previous CloseN/A
Volume58.77K
Average Volume (3M)2.04M
Market Cap
$729.82M
Enterprise Value$1.13B
Total Cash (Recent Filing)$294.73M
Total Debt (Recent Filing)$3.52M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Nov 18, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding134,993,530
10 Day Avg. Volume1,291,066
30 Day Avg. Volume2,043,175
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)-0.17
Price to Sales (P/S)2177.35
P/FCF Ratio-1.06
Enterprise Value/Market Cap1.55
Enterprise Value/Revenue2.14K
Enterprise Value/Gross Profit2.14K
Enterprise Value/Ebitda-7.17
Forecast
1Y Price Target
$5.80Price Target Upside133.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressProKidney Corp has made significant progress with more than half of the patients required for the accelerated approval analysis enrolled in the Phase 3 PROACT 1 study.
Financial StabilityProKidney has a cash runway into mid-2027, offering financial stability for ongoing operations and development.
Regulatory ApprovalThe FDA confirmed alignment on using eGFR as a surrogate endpoint in PROACT 1, supporting an accelerated approval path for rilparencel.
Bears Say
Program DisruptionThe prior pause to the registrational program proved to be more disruptive than expected.
Sentiment OverhangTimelines to accelerated approval data are longer than originally thought, potentially creating a sentiment overhang.
Trial RiskAnalyst maintains an Underperform rating and $1 price objective due to concerns around trial risk and a potentially niche end-market.
ProKidney News
PROK FAQ
What was Prokidney Corp.’s price range in the past 12 months?
Prokidney Corp. lowest stock price was $0.46 and its highest was $7.13 in the past 12 months.
What is Prokidney Corp.’s market cap?
Prokidney Corp.’s market cap is $729.82M.
When is Prokidney Corp.’s upcoming earnings report date?
Prokidney Corp.’s upcoming earnings report date is Nov 18, 2025 which is in 48 days.
How were Prokidney Corp.’s earnings last quarter?
Prokidney Corp. released its earnings results on Aug 12, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.144 by $0.014.
Is Prokidney Corp. overvalued?
According to Wall Street analysts Prokidney Corp.’s price is currently Undervalued.
Does Prokidney Corp. pay dividends?
Prokidney Corp. does not currently pay dividends.
What is Prokidney Corp.’s EPS estimate?
Prokidney Corp.’s EPS estimate is -0.14.
How many shares outstanding does Prokidney Corp. have?
Prokidney Corp. has 134,993,530 shares outstanding.
What happened to Prokidney Corp.’s price movement after its last earnings report?
Prokidney Corp. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.144. Following the earnings report the stock price went up 5.804%.
Which hedge fund is a major shareholder of Prokidney Corp.?
Currently, no hedge funds are holding shares in PROK
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.80 (133.87% Upside)
$5.80 (133.87% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 17.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.33%
12-Months-Change
Fundamentals
Return on Equity
4.66%
Trailing 12-Months
Asset Growth
-25.45%
Trailing 12-Months
Company Description
Prokidney Corp.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$5.80
▲(133.87% Upside)
Technical Analysis
Rezolute
―
Urogen Pharma
―
Phathom Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
82.51% Insiders
1.38% Mutual Funds
0.05% Other Institutional Investors
15.70% Public Companies and
Individual Investors